Skip to content

Changes in plasma and platelet Brain-Derived Neurotrophic Factor (BDNF) levels induced by S-citalopram in major depression

Utility of serum and platelet levels of Brain- Derived Neurotrofic Factor (BDNF) like biological marker of treatment response in major depression: a longitudinal controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11216093
Enrollment
32
Registered
2010-06-23
Start date
2005-07-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression Mental and Behavioural Disorders Depressive episode

Interventions

Patients group: After the baseline assessments and baseline blood samples were obtained, all patients were given S-citalopram orally as an antidepressant therapy. Beginning with 5 mg/day for 4 days,

Sponsors

Hospital Clinic of Barcelona (Hospital Clínic de Barcelona) (Spain)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient group: 1.1. Patients suffering from a current major depressive episode, single episode or recurrent, diagnosed according to Diagnostic and Statistical Manual for Mental Disorders Criteria 1.2. A 17-item Hamilton Depression Rating Scale (HDRS) total score of 18 or higher. 1.3. Aged between 18 and 65 years 2. Control group: 2.1. Healthy subjects with no history of chronic physical illness, substance abuse or mental diseases and not taking regular medications in the last month were recruited 2.2. Free of chronic and acute physical illness within the 2 weeks before the study 2.3. Aged between 18 and 65 years 3. Written information was given and written informed consent was obtained from each patient to participate

Exclusion criteria

Exclusion criteria: 1. Patient group: 1.1. Presence of other major axis I disorders, including schizophrenia, bipolar disorders, anxiety disorders, substance-related disorders and eating disorders 1.2. Presence of any acute physical disorders and/or exposure to any psychotropic drugs in the last month 2. Control group 2.1. History of chronic physical illness, substance abuse or mental diseases or taking regular medications in the last month 2.2. Free of chronic and acute physical illness within the 2 weeks before the study

Design outcomes

Primary

MeasureTime frame
BDNF levels in platelets and plasma, measured at baseline, 8 and 24 weeks of treatment in the patient group, once in the control group

Secondary

MeasureTime frame
1. Severity of depression was assessed using the 17-item Hamilton Depression Rating Scale (HDRS) 2. Cognitive performance, assessed by: 2.1. Wechsler Adult Intelligence Scale (WAIS-III): Vocabulary, Buckets of Kohs, numerical key similitudes 2.2. Wechsler Memory Scale (WMS-III): Digits, Verbal Memory I, Verbal Memory II 2.3. Train Making Test (TMT) part A and B 2.4. Auditory Verbal Learning Test (AVLT de Rey) (Rey 1964) 2.5. Stroop Color and Word Test 2.6. Wisconsin Card Sorting Test (WCST) 3. Quality of life scales: 3.1. Social Adaptation Self-evaluation Scalen (SASS) 3.2. Perceived Stress Scale (PSS) 3.3. Quality of Life in Depression Scale (QLDS) 4. Personality, assessed by Eysenck Personality Questionnaire (EPQ) Clinical assessments were conducted at baseline, 2, 4, 8, 12, 16, 20 and 24 weeks of treatment, once in the control group.

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026